This publication covers some of the latest advances in colorectal cancer treatment following recent read outs from clinical trials, as well as expert insights on how they approach therapy on an individualized basis.
Biweekly Cetuximab Offers a Convenient Dosing Option in mCRC
July 27th 2021Richard Kim, MD, discusses the utility of EGFR inhibitors in patients with RAS wild-type colorectal cancer, the convenience of biweekly dosing with cetuximab, recommendations for managing EGFR inhibitor–related treatment-related adverse effects, and novel combinations on the horizon.
GI Experts Discuss Treatment Dosing, Sequencing, and Future Directions in CRC
July 15th 2021Jaffar A. Ajani, MD, and Zev A. Wainberg, MD, discuss FDA updates regarding the dosing schedule of cetuximab for metastatic colorectal cancer and the value of real-word data on clinical practice patterns in the community when administering this drug.
Genomics, Sidedness Guide Treatment Selection in Metastatic CRC
July 14th 2021Zev A. Wainberg, MD, and Jaffer A. Ajani, MD, discuss how to best utilize information provided to inform treatment decisions, treatment approaches for patients with newly diagnosed RAS wild-type mCRC, and factors that affect influence selecting a 2- vs 3-drug chemotherapy regimen.
Next-Generation Sequencing in Metastatic Colorectal Cancer
June 1st 2021Drs Jaffer A. Ajani and Zev A. Wainberg comment on the rationale for conducting full next-generation sequencing panels on patients with metastatic colorectal cancer and explain how to best utilize information provided to inform treatment decisions.